Connect live...

Select the exhibitor's booth below and get connected live.

Click on "Edit" in the right panel to replace this with your own HTML code

Other exhibitors

Information

iCFO Information Booth How can we help?
Entrepreneur

PROOF Hard Ice Cream PROOF will be among the most highly recommended gourmet brands in the world
Entrepreneur

Gel Dynamics A Vetted Solution With A Global Market
Entrepreneur

Kurve Therapeutics The Future of Systemic and Central Nervous System (CNS) Therapies - Bringing solutions to clinical unmet needs
Entrepreneur

Addimmune Addimmune’s sole purpose is to cure HIV. We believe it’s possible with gene and cell therapy.
Entrepreneur

Adlore Introducing SenLore - A Novel Device to Treat and Monitor Diabetic Foot Ulcers
Entrepreneur

VIC Tech A LIFE SCIENCE VENTURE STUDIO - Building a Healthy Future
Entrepreneur

TracFlo A vertical SaaS Fintech focused on construction
Entrepreneur

MedAware Transforming patient safety
Entrepreneur

Greentech Laboratories ADVANCING HUMAN LIFE WITH TECHNOLOGIES FOR INNER WELLBEING
Entrepreneur

Creative BioTherapeutics WE START WHERE OTHER THERAPIES FAIL FOR RECURRENT & DRUG RESISTANT CANCERS
Entrepreneur

CommerceBlitz Optimizing Inventory and Distribution Operations for eCommerce Businesses
Entrepreneur

Titin KM Biomedical Corporation THE FUTURE OF SHOULDER REHABILITATION

Event DealConnect 360: The Ultimate Deal Room for Real Results! is over.
Join us next time to meet Noel Greenberger!

About Nob Hill Therapeutics

Nob Hill Therapeutics

Pioneering Respiratory Patient Care

Available from 12:00 PM - 4:00 PM (US/Pacific)

http://www.nobhilltherapeutics.com/

noel.greenberger@nobhilltherapeutics.com

+1 312-493-7881

Nob Hill Therapeutics is a healthcare startup that is developing new technologies and therapies for lung-related diseases that can’t be effectively treated today. These diseases impact millions of patients, and the annual market potential for several of these diseases is substantial (e.g., lung cancer - $30b, Cystic Fibrosis - $13b, Invasive fungal infections - $9b). Nob Hill has developed a new drug inhalation device platform that solves many disadvantages with today’s technologies and also is working on accompanying drug-device combination products that will serve as PoC for the technology (with addressable markets in the US of $1.75b annual sales). Nob Hill’s team is highly experienced with developing and commercializing respiratory products (combined experience of 100+ years).